Bruker (BRKR) Stock Forecast & Price Target

Q: What is BRKR’s average 12-month price target, according to analysts?

Based on analyst ratings, Bruker Corp’s 12-month average price target is 44.89.

Q: What is BRKR’s upside potential, based on the analysts’ average price target?

Bruker Corp has 39.80% upside potential, based on the analysts’ average price target.

Q: Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

Q: How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Q: Is BRKR a Buy, Sell or Hold?

Bruker Corp has a consensus rating of Moderate Buy which is based on 6 buy ratings, 4 hold ratings and 0 sell ratings.

Q: What is Bruker Corp’s price target?

The average price target for Bruker Corp is 44.89. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $60.00 ,the lowest forecast is $38.00. The average price target represents 39.80% Increase from the current price of $32.11.

Q: What do analysts say about Bruker Corp?

Bruker Corp’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.

Q: How can I buy shares of BRKR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Compare

443 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BRKR Analyst Ratings

Moderate Buy

6 Buy

4 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Bruker

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BRKR Stock 12 Month Forecast

Average Price Target

$44.89

▲(39.80% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Bruker in the last 3 months. The average price target is $44.89 with a high forecast of $60.00 and a low forecast of $38.00. The average price target represents a 39.80% change from the last price of $32.11.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"32":"$32","67":"$67","40.75":"$40.8","49.5":"$49.5","58.25":"$58.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":44.89,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$44.89</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$38.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[32,40.75,49.5,58.25,67],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.23,35.28923076923077,37.348461538461535,39.40769230769231,41.466923076923074,43.526153846153846,45.58538461538461,47.644615384615385,49.70384615384616,51.76307692307692,53.82230769230769,55.88153846153846,57.940769230769234,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.23,34.12692307692308,35.02384615384615,35.92076923076923,36.817692307692305,37.714615384615385,38.61153846153846,39.50846153846154,40.40538461538461,41.30230769230769,42.199230769230766,43.09615384615385,43.99307692307693,{"y":44.89,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.23,33.596923076923076,33.96384615384615,34.33076923076923,34.69769230769231,35.06461538461538,35.43153846153846,35.79846153846154,36.16538461538462,36.53230769230769,36.89923076923077,37.26615384615385,37.63307692307692,{"y":38,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":66.97,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.54,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.1,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.23,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.48,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.01,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.11,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.33,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.3,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.68,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.99,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.23,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$60.00

Average Price Target$44.89

Lowest Price Target$38.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Puneet Souda

Leerink Partners

―

Buy

―

Reiterated

09/07/25

Bruker Positioned for Recovery and Growth Amid Financial Maneuvering and Strategic InitiativesWe recently caught up with BRKR mgmt. (CEO the close of their recent convertible financing of ~$670M to address term loans due Dec 2026, partial loans due 2027 and also the revolver credit agreement from 2024. According to mgmt., 1) the capital raise lifts the overhang from the 2026-27 debt covenants which required a leverage ratio below <3.5x; and 2) with the overhang behind, investors are more likely to get involved at currently attractive valuations despite the macro headwinds. Feedback from mgmt. also suggests that the interest level was relatively strong from investors at the depressed valuation (10.6x EV/EBITDA), despite the dilution in shares (mandatory conversion between $29.35 - $35.95).

Michael Ryskin

Bank of America Securities

$43

Buy

33.91%

Upside

Reiterated

09/05/25

Bruker Positioned for Growth with Strategic Financial Moves and Cost Savings Initiatives

Lila Implantra

TR | OpenAI - 4o

$36→$30

Hold

-6.57%

Downside

Reiterated

09/04/25

AI Generated ArticleAI Generated Article

Daniel Brennan

TD Cowen

$40

Hold

24.57%

Upside

Reiterated

09/03/25

TD Cowen Sticks to Their Hold Rating for Bruker (BRKR)

Brandon Couillard

Wells Fargo

$60→$50

Buy

55.71%

Upside

Reiterated

08/06/25

Bruker (BRKR) Gets a Buy from Wells Fargo

Dan Leonard

UBS

$45→$40

Hold

24.57%

Upside

Reiterated

08/05/25

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN), Waters (NYSE: WAT) and Bruker (NASDAQ: BRKR)

Rachel Vatnsdal

J.P. Morgan

$60→$50

Buy

55.71%

Upside

Reiterated

08/05/25

Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (NASDAQ: ALLO), Vertex Pharmaceuticals (NASDAQ: VRTX) and Bruker (NASDAQ: BRKR)

Daniel Arias

Stifel Nicolaus

$48→$40

Hold

24.57%

Upside

Reiterated

08/05/25

Bruker price target lowered to $40 from $48 at StifelBruker price target lowered to $40 from $48 at Stifel

Tycho Peterson

Jefferies

$70→$60

Buy

86.86%

Upside

Reiterated

08/04/25

Bruker price target lowered to $60 from $70 at JefferiesBruker price target lowered to $60 from $70 at Jefferies

Patrick B Donnelly

Citi

$40→$38

Hold

18.34%

Upside

Reiterated

08/04/25

Bruker price target lowered to $38 from $40 at CitiBruker price target lowered to $38 from $40 at Citi

Luke Sergott

Barclays

$46→$43

Buy

33.91%

Upside

Reiterated

08/04/25

Bruker price target lowered to $43 from $46 at BarclaysBruker price target lowered to $43 from $46 at Barclays

Unknown Analyst

Cleveland Research

Not Ranked

Cleveland Research

―

Hold

―

Downgraded

04/24/25

Cleveland Research downgrades Bruker (BRKR) to NeutralCleveland Research downgraded Bruker (NASDAQ: BRKR) from Buy to Neutral.

Subbu Nambi

Guggenheim

―

Buy

―

Reiterated

02/21/25

Matthew Sykes

Goldman Sachs

―

Hold

―

Upgraded

12/05/24

Goldman Sachs upgrades Bruker (BRKR) to NeutralGoldman Sachs analyst Matthew Sykes upgraded Bruker (NASDAQ: BRKR) from Sell to Neutral with a price target of $60.00.

Doug Schenkel

Wolfe Research

―

Hold

―

Downgraded

09/30/24

Bruker (BRKR) was downgraded to a Hold Rating at Wolfe Research

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Puneet Souda

Leerink Partners

―

Buy

―

Reiterated

09/07/25

Michael Ryskin

Bank of America Securities

$43

Buy

33.91%

Upside

Reiterated

09/05/25

Bruker Positioned for Growth with Strategic Financial Moves and Cost Savings Initiatives

Lila Implantra

TR | OpenAI - 4o

$36→$30

Hold

-6.57%

Downside

Reiterated

09/04/25

AI Generated ArticleAI Generated Article

Daniel Brennan

TD Cowen

$40

Hold

24.57%

Upside

Reiterated

09/03/25

TD Cowen Sticks to Their Hold Rating for Bruker (BRKR)

Brandon Couillard

Wells Fargo

$60→$50

Buy

55.71%

Upside

Reiterated

08/06/25

Bruker (BRKR) Gets a Buy from Wells Fargo

Dan Leonard

UBS

$45→$40

Hold

24.57%

Upside

Reiterated

08/05/25

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN), Waters (NYSE: WAT) and Bruker (NASDAQ: BRKR)

Rachel Vatnsdal

J.P. Morgan

$60→$50

Buy

55.71%

Upside

Reiterated

08/05/25

Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (NASDAQ: ALLO), Vertex Pharmaceuticals (NASDAQ: VRTX) and Bruker (NASDAQ: BRKR)

Daniel Arias

Stifel Nicolaus

$48→$40

Hold

24.57%

Upside

Reiterated

08/05/25

Bruker price target lowered to $40 from $48 at StifelBruker price target lowered to $40 from $48 at Stifel

Tycho Peterson

Jefferies

$70→$60

Buy

86.86%

Upside

Reiterated

08/04/25

Bruker price target lowered to $60 from $70 at JefferiesBruker price target lowered to $60 from $70 at Jefferies

Patrick B Donnelly

Citi

$40→$38

Hold

18.34%

Upside

Reiterated

08/04/25

Bruker price target lowered to $38 from $40 at CitiBruker price target lowered to $38 from $40 at Citi

Luke Sergott

Barclays

$46→$43

Buy

33.91%

Upside

Reiterated

08/04/25

Bruker price target lowered to $43 from $46 at BarclaysBruker price target lowered to $43 from $46 at Barclays

Unknown Analyst

Cleveland Research

Not Ranked

Cleveland Research

―

Hold

―

Downgraded

04/24/25

Cleveland Research downgrades Bruker (BRKR) to NeutralCleveland Research downgraded Bruker (NASDAQ: BRKR) from Buy to Neutral.

Subbu Nambi

Guggenheim

―

Buy

―

Reiterated

02/21/25

Matthew Sykes

Goldman Sachs

―

Hold

―

Upgraded

12/05/24

Goldman Sachs upgrades Bruker (BRKR) to NeutralGoldman Sachs analyst Matthew Sykes upgraded Bruker (NASDAQ: BRKR) from Sell to Neutral with a price target of $60.00.

Doug Schenkel

Wolfe Research

―

Hold

―

Downgraded

09/30/24

Bruker (BRKR) was downgraded to a Hold Rating at Wolfe Research

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Bruker

1 Month

xxx

Success Rate

15/32 ratings generated profit

Average Return

+0.04%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 46.88% of your transactions generating a profit, with an average return of +0.04% per trade.

3 Months

xxx

Success Rate

13/32 ratings generated profit

Average Return

-3.71%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 40.63% of your transactions generating a profit, with an average return of -3.71% per trade.

1 Year

Brandon CouillardWells Fargo

Success Rate

16/32 ratings generated profit

Average Return

-0.98%

reiterated a buy rating last month

Copying Brandon Couillard's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -0.98% per trade.

2 Years

xxx

Success Rate

20/32 ratings generated profit

Average Return

+5.14%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 62.50% of your transactions generating a profit, with an average return of +5.14% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BRKR Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BRKR has received 12 Buy Ratings, 15 Hold Ratings, and 0 Sell Ratings. BRKR average Analyst price target in the past 3 months is 44.89.

Each month's total comprises the sum of three months' worth of ratings.

BRKR Financial Forecast

BRKR Earnings Forecast

Next quarter’s earnings estimate for BRKR is $0.33 with a range of $0.30 to $0.36. The previous quarter’s EPS was $0.32. BRKR beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.22% of the time in the same period. In the last calendar year BRKR has Outperformed its overall industry.

BRKR Sales Forecast

Next quarter’s sales forecast for BRKR is $848.44M with a range of $838.14M to $859.30M. The previous quarter’s sales results were $797.40M. BRKR beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.12% of the time in the same period. In the last calendar year BRKR has Outperformed its overall industry.

BRKR Stock Forecast FAQ

What is BRKR’s average 12-month price target, according to analysts?

Based on analyst ratings, Bruker Corp’s 12-month average price target is 44.89.

What is BRKR’s upside potential, based on the analysts’ average price target?

Bruker Corp has 39.80% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BRKR a Buy, Sell or Hold?

Bruker Corp has a consensus rating of Moderate Buy which is based on 6 buy ratings, 4 hold ratings and 0 sell ratings.

What is Bruker Corp’s price target?

The average price target for Bruker Corp is 44.89. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $60.00 ,the lowest forecast is $38.00. The average price target represents 39.80% Increase from the current price of $32.11.

What do analysts say about Bruker Corp?

Bruker Corp’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of BRKR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Bruker (BRKR) Stock Forecast & Price Target

BRKR Analyst Ratings

BRKR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Bruker

BRKR Analyst Recommendation Trends

BRKR Financial Forecast

BRKR Earnings Forecast

BRKR Sales Forecast

BRKR Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts